Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Personalized 1st-line Treatment of Patients With NSCLC: is Timely Analysis of EGFR-mutation Status Feasible in a Routine Practice Setting in Antwerp.

NCT01260038 is registered in ClinicalTrials.gov with University Hospital, Antwerp as lead sponsor.

NCT NCT01260038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01260038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Personalized 1st-line Treatment of Patients With NSCLC: is Timely Analysis of EGFR-mutation Status Feasible in a Routine Practice Setting in Antwerp.
Lead sponsor
University Hospital, Antwerp
Phase
Observational
Overall status
Completed
Start date
November 30, 2010
Completion date
September 30, 2011
Enrollment
107 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer